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Background: Erythema infectiosum is the most common clinical manifestation of Parvovirus B19 infection although
it has also been associated with rheumatologic diseases and various types of systemic vasculitides. Acute hepatitis
and benign myositis however are rarely reported in association with Parvovirus B19 infection.
Case presentation: Here we report a 14-year old male, who developed acute hepatitis and benign myositis associated
with erythema infectiosum following Parvovirus B19 infection.
Conclusion: Parvovirus B19 infection has rarely been associated with acute hepatitis and exceptionally rarely with
benign myositis. Parvovirus B19 should be considered in the differential diagnosis of acute non-A to E hepatitis and in
the case of acute benign myositis presenting with a rash especially in children.
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Parvovirus is a ubiquitous agent commonly infecting chil-
dren. By 15 years of age, half of children are seropositive
to the virus [1]. Parvovirus B19 belongs to the erythrovirus
genus, which was named after its pronounced tropism for
erythrocyte precursor cells. Erythema infectiosum is the
most common clinical manifestation of Parvovirus B19 in-
fection transmitted mainly by respiratory droplets, which
often occurs in outbreaks among school-aged children.
The illness usually starts with fever and non-specific
influenza-like symptoms followed by rash, fever and
rheumatic symptoms such as arthralgia or arthritis [2].
In 25% to 50% of cases in immunocompetent patients,
infection by Parvovirus B19 is entirely asymptomatic
[3]. There are, however, well characterized clinical syn-
dromes associated with infection. Apart from erythema
infectiosum, these include non-immune hydrops fetalis
and arthropathy [1]. Acute hepatitis has rarely been
associated with Parvovirus B19 infection [4-7] and its* Correspondence: mkoliou@spidernet.com.cy
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reproduction in any medium, provided the orassociation with benign myositis is exceptionally rare
with only one case having been reported in the litera-
ture [8].
In the current case report, we present a 14-year old
adolescent who developed acute benign hepatitis and
concurrent myositis in the context of erythema infectio-
sum caused by Parvovirus B19.Case presentation
A 14-year old white male, was transferred to our hos-
pital in June 2012 from the Paediatric department of a
district hospital because of arthralgias, myalgias and
chest pain. The patient was well until 48 hours prior to
admission when he started to complain of pain mainly
in the upper limbs and chest. The next day he developed
fever, rash, malaise and worsening chest pain. A few
hours before his visit to the Accident and Emergency de-
partment of the district hospital he had a short syncope
episode. On the same day he started to feel weakness in
both upper and lower limbs, he was unable to walk and
was admitted to the district hospital.
The child’s medical history was significant for oral anti-
biotic therapy for an infected epidydymal cyst. Initially heLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for 7 days and co-trimoxazole for another 7 days. The
antibiotic therapy was completed one week before the de-
scribed health problem. In the two years preceding the
episode he had reported two episodes of non-specific al-
lergic rashes.
The laboratory work-up performed on admission at
the tertiary referral hospital revealed elevated creatinine
phosphokinase (CPK) 7,643 U/L and CK-MB isoenzyme
75.8 U/L. Troponin levels were < 50 mg/dl, alanine amino-
transferase 180 U/L, aspartate aminotransferase 253 U/L,
γ-GT 72 U/L, alkaline phosphatase 146 U/L, total bili-
rubin 3.14 mg/dl with direct component 1.04 mg/dl.
International normalised ratio (INR) was 1.34, and lactate
dehydrogenase 760 U/L.
On the third day of hospitalization the child was trans-
ferred to our hospital as a referral and on admission he
was relatively well with normal vital signs and temperature
37.6°C. On examination, he had an erythematous rash
over the face with relative circumoral pallor. An erythe-
matous maculopapular rash was also present over the en-
tire trunk and the extremities. His muscle strength on the
upper and lower limbs was decreased (2/5), and the mus-
cles, especially the calves, were slightly painful on palpa-
tion, but there was no swelling. The child was unable to
walk even after 6 days of hospitalization. In addition, he
was complaining of arthralgias especially of the elbow
joints but no findings suggestive of arthritis were detected.
No abnormal findings were detected from cardiac, respira-
tory and abdominal examination.
The rash disappeared on the 7th day leaving the lower
limbs with a reticulated or lacelike rash more visible
during standing and after bathing. His workup included
cardiology evaluation with normal ECG, echocardiogram
and serial laboratory tests for re-evaluation of his liver
function and CPK (Table 1).Table 1 Laboratory results of the patient during hospitalizati
district hospital)
Laboratory test (normal range) Day 4 Day 5 D
CPK (26 – 171 U/L 7643 5168
CK-MB (0 – 25 U/L) 75.8 44
ALT (3 – 41 U/L) 180 161
AST (3 – 38 U/L) 253 207
INR (0.95 – 1.02) - 1.30
γ-GT (9 – 55 U/L) 72 92
T. Bilirubin (0.3 – 1.2 mg/dl) 3.14 3.04
Direct Bilirubin (0.1 – 0.2 mg/dl) 1.04 1.60
LDH (208 – 480 U/L) 760 700
Hb (g/dl) 14.7 13.4
CRP (neg < 0.5 mg/dl) 9.3 12.0
ESR (mm) - 14In summary, the liver enzymes and CPK normalized
by day 11. Additional laboratory tests included anti-
streptolysin titer 237 IU/ml (normal 0 - 350 IU/ml),
negative anti-nuclear antibodies (ANA), negative Myco-
plasma IgM, and negative viral studies for IgM anti-
bodies for EBV, CMV, Adenovirus, Measles, and Rubella.
Antibodies for hepatitis A, C and Hepatitis B surface
antigen were also negative. Serum, lymphocytes and
stools were negative for enterovirus RNA and adenovirus
DNA as detected by TaqMan based RealTime PCR
methods (qualitative assays). Parvovirus B19 DNA as de-
tected by TaqMan based RealTime PCR method [9] was
positive in the serum and lymphocytes. No quantitative
PCR was done. IgG for Parvovirus B19 were strongly
positive, whereas IgM negative.
During hospitalization the patient was treated with
penicillin 100,000 IU/kg/24h IV for two days and then
switched to cefotaxime 100 mg/kg/24h and azithromycin
500 mg/day to complete a 3-day regimen because of
high-grade fever, cough and malaise. Blood culture was
negative. On day 8 he became afebrile, while his muscle
strength returned to normal levels at day 9, when he was
able to walk without pain and at day 11 he was discharged
home afebrile and in good condition.
Conclusions
Erythema infectiosum is the most common clinical mani-
festation of Parvovirus B19 infection transmitted mainly
by respiratory droplets. The illness usually runs in a bi-
phasic course, which starts with fever and non-specific
flu-like symptoms [2] followed by rash, fever and rheuma-
tologic manifestations such as arthralgia or arthritis. The
second phase develops concurrently with the production
of detectable anti-viral antibodies, therefore it is believed
that these symptoms are at least partially due to theon and follow up (days counted since admission in the
ay 6 Day 7 Day 11 One month follow up
2463 325 51 83
- - - -
130 92 78 20
133 59 36 28
1.45 1.37 1.02 -
95 101 78 17
- - 1.12 1.02
- - 0.30 -
457 538 433 428
12.9 12.7 13.5 15.3
11.0 9.6 2.0 0.1
16 21 34 9
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tissues [1]. A temporary suppression of erythropoiesis
usually occurs during the first phase of Parvovirus infec-
tion, which is however recognizable only in patients with
chronic haemolytic disorders [3].
Acute hepatitis has rarely been associated with Parvo-
virus B19 infection [4-6,10]. In most of these cases the
outcome was favourable, although, in one case, hepatitis
lasted for up to 9 months [7]. Some studies have impli-
cated Parvovirus B19 in cases of liver failure as a result
of fulminant hepatitis; however, other studies did not
support this association [11,12]. In our case, hepatitis
was rather mild. There was an increase in the transamin-
ase levels and the bilirubin and there was evidence of
mild hepatic dysfunction as evidenced by an increase of
INR; however, the liver abnormalities self-resolved in a
few weeks.
The mechanism by which Parvovirus B19 causes hep-
atic injury has not been elucidated. Two mechanisms
have been proposed: One refers to a direct invasion by
the virus that can cause hepatic cell damage [13], while
the other involves an indirect action mainly triggered by
an immune response against the virus [14]. On the cellu-
lar level, globoside, a neutral glycolipid, acts as the main
cell receptor for the virus and can be found abundantly
on the cell membranes of the erythrocyte and its precur-
sors. This provides a possible explanation for most of
the underlying pathology linked to the manifestations of
Parvovirus B19 infection including transient aplastic
crisis and hydrops fetalis [15]. Globoside has also been
detected on the membranes of many other cell types in
the human body including the hepatocytes [16]. It seems
that all non-erythroid cells are not permissive to the
virus, meaning that despite the virus gains entry into the
cells, it cannot replicate [3]. However, it has been sug-
gested that despite the virus inability to replicate within
a non permissive cell, it retains its ability to produce the
non structural protein NS1, which can induce apoptosis
of the corresponding infected cell [13,17]. This has also
been proposed in the case of the hepatocyte and sup-
ports the hypothesis of the direct cytopathic effect of
Parvovirus B19 on liver cells [13].
Co-trimoxazole, administered a week prior to illness
could in rare instances result in a similar clinical picture.
Most side effects are thought to be due to sulfonamide
component. A hypersensitivity syndrome can be induced
consisting of fever, rashes and organ involvement of
varying severity. The rash may be of different types in-
cluding maculopapular or urticarial type but erythema
nodosum, exfoliative dermatitis can also occur usually in
association with arthralgias [18]. The liver damage is
usually mild, consists of a mild transaminase elevation
and resolves within a few weeks. However, in rare cases
it may progress to fulminant liver failure [19-21].In our case, some manifestations such as the liver en-
zyme increase could partially be attributed to the previ-
ous administration of co-trimoxazole. However, the lacy
appearance of the rash was very characteristic of parvo-
virus infection. Furthermore, to our knowledge, myositis
was never reported in the literature in association to ei-
ther trimethoprim or sulfonamides. Eosinophilia, a fre-
quent finding associated with hypersensitivity related
manifestations of sulfonamides, was undetected in our
case.
In some cases, Parvovirus B19 has been associated
with rheumatologic disease in both children and adults
[22] and with various types of systemic vasculitis, which
include cases of dermatomyositis [7,23]. In our patient,
myositis may be differentiated from previously reported
dermatomyositis cases mainly because of its very short
and benign course and the fact that auto-antibodies such
as ANA were all negative. Up to now, about one year
after the episode, the patient remains completely healthy.
An electromyogram was not performed on the patient
because of the rapid improvement of his condition. The
very short course and self-resolution of myositis in our
patient supports the hypothesis that the underlying
mechanism is much more benign and self-limited. The
myositis in our patient could probably fit more into the
context of acute benign childhood myositis (BACM) as
the one encountered at the early convalescent period of
several viral infections including influenza [24]. BACM
is a very benign condition, which follows a few days after
a flu-like illness. The CPK is invariably elevated in all
such cases. The calf muscles are mainly affected result-
ing in weakness and inability to walk. In our case the
muscle weakness and elevated CPK was detected during
the stage of the rash and arthralgia, which may represent
the stage of production of antibodies and the formation
of immune complexes [1].
One of the hypotheses in the pathogenesis of BACM
associated with influenza virus infection is the direct in-
vasion of the muscle cells by the virus, which however is
not permissive and therefore does not allow the virus to
replicate within the muscle cells. Therefore the initial in-
fection of the muscle tissue by the virus results in some
muscle fibre necrosis sufficient to cause elevation of the
CPK but does not cause a frank inflammation of the
muscle tissue [25]. However, as in the case of hepatitis,
there is still uncertainty as to whether the myositis is
caused by the direct invasion of the virus or whether an
immune mediated mechanism triggered by the virus
leads to muscle injury [26]. Unfortunately, we were un-
able to clarify this hypothesis since a biopsy was not per-
formed due to the short course of illness.
To our knowledge, there is only one similar case re-
port of benign myositis during infection by Parvovirus
B19 [8]. That case developed in the context of Erythema
Koliou et al. BMC Pediatrics 2014, 14:6 Page 4 of 4
http://www.biomedcentral.com/1471-2431/14/6infectiosum caused by Parvovirus B19 in a 9-year old
child and was also self resolved a few days later. Our
case and the one previously reported add to the scientific
knowledge associating Parvovirus B19 with a wide range
of diseases in both children and adults. Furthermore, it
shows that Parvovirus B19 should be considered in the
differential diagnosis of acute non-A to E hepatitis and
also in the case of acute benign myositis associated with
viral infections presenting with a rash.
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